قالب وردپرس درنا توس
Home https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Health https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Breast cancer study to 44% better survival

Breast cancer study to 44% better survival



Surgery to remove tumors has been associated with a 44% increased chance of survival within an average follow-up period of 21 months, according to the abstract, to be presented at the American Association for Cancer Research's annual meeting in Atlanta this week.

"If breast surgery is to be considered by patients and providers when deciding treatment strategies, it will be imperative to address significant disparities among patients who are offered surgical therapy," the researchers wrote. , 89.4%, were treated with chemotherapy or immunotherapy; 37.7% underwent endocrine therapy; and 31.8% underwent radiation. Overall, 35%, or 1,130 women underwent surgery; the rest did not.

Surgery was more likely to be performed in patients with private insurance or Medicare than in those who were uninsured or on Medicaid; those in the lowest income quartile compared to the highest; and those who received other treatments, said Dr. Sharon Lum, a professor and medical director of the Breast Health Center and Loma Linda University in California, who was the senior author of the study

"Surgery was less likely to be performed in older patients than non-Hispanic black compared with community programs, and those with a larger tumor size, "she said.

The study also looked into the treatment options with other treatment options available to patients, such as targeted medications, said Ross Mudgway, and a medical student at the University of California, Riverside School of Medicine, who was the first author of the study.

The findings suggest that surgery to remove a breast tumor should be considered in addition to standard targeted medications and other therapies if a woman has stage 4 HER2-positive breast cancer

"We hope that our results will encourage clinicians to consider surgical treatment in the face of metastatic disease while weighing the risks and potential benefits in this particular subset of patients who have new, effective targeted treatment options, "Mudgway said.

The study had some limitations, including that there was only an association found between surgery and

HER2-positive cancers are much more likely to benefit from treatment with drugs that specifically target the protein, according to the American Cancer Society

Additionally, "We have not yet randomized controlled trial results that address the impact of surgical removal of breast cancer in patients with HER2-positive metastatic breast cancer," said Lum.

"So using observational data from the large NCDB dataset can help address the questions about surgical treatment that providers and patients are asking today. "

 Many women with commo (1[ads1]9459015) </noscript> </div>
</p></div>
</p></div>
<p> Many women with common breast cancer can safely skip chemo, study says ” class=”media__image” src=”http://cdn.cnn.com/cnnnext/dam/assets/180502144732-mammogram-stock-large-169.jpg”/> Traditionally, surgery has been a standard part of </p>
<div class= Yet in stage 4 metastatic breast cancer, "it does not make sense to cut out cancer in the breast if there is cancer in other parts of the body," said Dr. Monica Morrow, a surgical oncologist and chief of breast surgery at the Department of Surgery at the Memorial Sloan Kettering Cancer Center in New York, who was not involved in the study

"The patients who had had surgery were the ones who had better responses this chemotherapy probably had less metastatic disease and were probably healthier, "she said. "So maybe they lived longer because of surgery, or perhaps they would have lived longer anyway, and the study shows that doctors know how to identify patients who will do well."

In other words, more research is needed to determine whether these factors are influencing the new study's findings, since databases – like those used in the new study – may sometimes suffer from a selection bias.

"The question of a benefit for surgery can only be answered by a prospective randomized trial , "Morrow said.

She added that another researcher in the field, Dr. Seema Khan, a professor of cancer research at Northwestern University's Feinberg School of Medicine, has been leading such a trial

"We eagerly await the results," Morrow said. Tari King, chief of breast surgery at the Dana-Farber / Brigham and Women's Cancer Center in Boston, called the new study "interesting" but cautioned that the findings should not be over-interpreted since "there are many biases"

For example, patients with a good response to first-line or initial therapy would have been selected for subsequent surgery, "whereas those whose disease was refractory to first-line "Therapies and benefits of local therapy – surgery plus radiation – for breast cancer are favorable when surgery is a surgery," said King. being performed for curative intent, "she said.


Source link